Supernus won a meaningful procedural victory that tightens the path to generic Qelbree for most defendants. The restricted invalidity theories improve the probability of maintaining patent exclusivity through 2028. However, Zydus still advances its more complete invalidity arguments, and the case remains in early stages with claim construction and trial ahead. Monitor for Markman rulings, settlement developments, and any appeal by the non-Zydus defendants.
Price Chart
Executive Summary
Supernus Pharmaceuticals won a procedural ruling in its Hatch-Waxman patent infringement action against multiple generic defendants seeking to market generic Qelbree. The court denied non-Zydus defendants' request to amend their invalidity contentions to adopt additional prior art theories that rival Zydus had separately asserted, finding they failed to show good cause or diligence. This ruling limits the scope of invalidity arguments available against Supernus's method-of-treatment patents but does not resolve the underlying case or affect Zydus's separate contentions.
Court Ruling Details
Key Facts
- Court denied non-Zydus defendants' motion to amend invalidity contentions to adopt Zydus's additional prior art references (Martin, Pataki, Spencer) for method-of-treatment patents covering Qelbree (viloxazine).
- Ruling affirms Supernus's patent positions against generic challengers Appco Pharma, Apotex, Aurobindo, MacLeods, MSN, Zenara, and Biophore - restricting their invalidity theories to what they originally served.
- Standard 30-month Hatch-Waxman stay is extended through October 2, 2028, due to new chemical entity exclusivity status and timing of litigation filing.
- Zydus defendants (Zydus Lifesciences, Zydus Pharmaceuticals (USA) Inc.) still maintain their separate invalidity contentions on method-of-treatment patents - the ruling does not apply to them.
Financial Impact
Ruling narrows invalidity defenses for most generic challengers on method-of-treatment patents that protect Qelbree through at least October 2028. Qelbree is Supernus's key branded ADHD product; blocking generic entry preserves revenue stream but case remains unresolved.
Risk Factors
- Zydus defendants retain the additional prior art contentions the court denied other defendants from adopting.
- This is an interlocutory procedural ruling - it does not resolve the overall patent validity or infringement questions.
- Non-Zydus defendants may seek leave to appeal or pursue other avenues to introduce the prior art.
- Historical trading pattern on SUPN filings shows poor near-term alpha, suggesting the market may not price this positively.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-c758a8ba4f-SUPN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $42.60 (+2.68%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | 8-K | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | DEFA14A / 425 / 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Jul 22, 2026 10w ago | 8-K | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 22, 2026 10w ago | Press Release | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 20, 2026 10w ago | Court Ruling | $47.42 $46.20 | ▼ −2.57% | ▼ −2.15% | $42.60 (−10.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access